Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study

Robert F. Sidonio Jra Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USAView further author information

Alexis A. Thompsonb Division of Hematology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USAView further author information

Flora Peyvandic Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre and Fondazione Luigi Villa, Milan, Italy;d Department of Pathophysiology and Transplantation, Universitàdegli Studi diMilano, Milan, ItalyView further author information

Oleksandra Stasyshyne Academy of Medical Sciences of Ukraine, Lviv, UkraineView further author information

Seoh Leng Yeohf Department of Pediatrics, Hospital Pulau Pinang, George Town, MalaysiaView further author information

Darintr Sosothikulg Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand;h Integrative and Innovative Hematology/Oncology Research Unit, Faculty of Medicine, Chulalonkorn University, Bangkok, ThailandView further author information

Ali Bulent Antmeni Department of Pediatric Hematology and Oncology, Acibadem Adana Hospital, Adana, TurkeyView further author information

Caterina Maggiorej IQVIA, Milan, ItalyView further author information

Werner Englk Pharmacometrics & Biostatistics, Baxalta Innovations GmbH, A Takeda Company, Vienna, AustriaView further author information

Bruce Ewensteinl Takeda Development Center Americas, Inc., Cambridge, MA, USAView further author information

Srilatha Tangadal Takeda Development Center Americas, Inc., Cambridge, MA, USACorrespondence[email protected]
View further author information

show all

Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date